Peptides / Longevity and mitochondria

Synthetic analog · 3 amino acids · 390.4 Da

Vesugen (KED)

Vesugen is a short synthetic peptide (Lys-Glu-Asp) from the Khavinson bioregulator family, sold in Russia as a dietary supplement. Most results come from lab cells, with a few small studies in people on markers of aging and blood vessels. PepBank shows 5 results on Vesugen from 3 studies in people, and 18 from animal and lab studies. The strongest evidence is a trial in people without random groups. Data as of 2026-10-30.

Also known as KED, Lys-Glu-Asp, Vesugen, Vesugen peptide, Vezugen

3 amino acids, from first to lastKED

Evidence level: Mostly animal studies18 of 23 results come from studies in animals and lab cells. 3 studies in people.

Results in people

22% of 23 results

Results in animals

0% of 23 results

Results in lab cells

78% of 23 results

From computer models

0% of 23 results

Overview

Vesugen (KED) at a glance

What it is	Synthetic analog, 3 amino acids
Approval	Regulatory status not recorded
In sport	Status unknown
Studies	13 studies with results. 10 of them gave Vesugen, with 23 results. 5 in people18 in lab cells
Best study in people	Non-randomized trial with 41 people (2014)
Clinical trials	None registered
Community use	Community interest in blood vessel aging research

The science

What is Vesugen?

Synthetic Lys-Glu-Asp peptide from the Khavinson bioregulator family.

Amino acids in one chain

Vesugen (KED) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 3 amino acidsFrom the first amino acid to the last

+K1−E−D

Darker means more water-repelling+ and − show charge in the body

Structure

Vesugen (KED) is a synthetic analog of 3 amino acids, with no ring, no changed amino acids.

Formula

C₁₅H₂₆N₄O₈

Molecular weight

390.4 g/mol

CAS number

204271-66-9

Development

Highest phase: no known clinical development.

Identifiers

PubChem 87571363

Full sequence, SMILES and InChIKey

Three-letter sequence
H-Lys-Glu-Asp-OH

InChIKey
LLSUNJYOSCOOEB-GUBZILKMSA-N

SMILES
C(CCN)C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)O)N

See charge, composition and 3D structure on the Scientific page

The evidence

What Vesugen studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Mostly animal studies18 of 23 results come from studies in animals and lab cells. 3 studies in people.

Cells, genes and aging

11 results · 2 in people · 9 lab

In these patients, Vesugen showed a greater reported effect against aging than Pinealon. Advances in gerontology = Uspekhi gerontologii, 2015

Top results

In these patients, Vesugen showed a greater reported effect against aging than Pinealon. (Advances in gerontology = Uspekhi gerontologii, 2015)
In patients with several diseases and organic brain syndrome in remission, Vesugen increased anabolic activity. (Advances in gerontology = Uspekhi gerontologii, 2015)
In cells, vesugen increased proliferation-associated Ki-67 protein. (Advances in gerontology = Uspekhi gerontologii, 2014)

Heart and blood vessels

1 result · 1 in people

In patients after surgery for leg ischemia, Vezugen improved leg blood flow on clinical and ultrasound measures compared with before treatment. Advances in gerontology = Uspekhi gerontologii, 2013

Top results

In patients after surgery for leg ischemia, Vezugen improved leg blood flow on clinical and ultrasound measures compared with before treatment. (Advances in gerontology = Uspekhi gerontologii, 2013)

Sexual and women's health

1 result · 1 in people

In patients with vascular erectile dysfunction, Vezugen improved penile arterial blood flow compared with before treatment. Advances in gerontology = Uspekhi gerontologii, 2014

Top results

In patients with vascular erectile dysfunction, Vezugen improved penile arterial blood flow compared with before treatment. (Advances in gerontology = Uspekhi gerontologii, 2014)

Immune system and inflammation

2 results · 2 lab

In lab tests, vesugen did not change the ability of pineal immune cells to differentiate. Bulletin of experimental biology and medicine, 2011

Top results

In lab tests, vesugen did not change the ability of pineal immune cells to differentiate. (Bulletin of experimental biology and medicine, 2011)
In lab tests, vesugen increased the ability of pineal immune cells to multiply. (Bulletin of experimental biology and medicine, 2011)

All 3 studies in people

In people

In patients with vascular erectile dysfunction, Vezugen improved penile arterial blood flow compared with before treatment.

2014Advances in gerontology = Uspekhi gerontologii41 people

In people

In patients after surgery for leg ischemia, Vezugen improved leg blood flow on clinical and ultrasound measures compared with before treatment.

2013Advances in gerontology = Uspekhi gerontologii41 people

In people

In these patients, Vesugen showed a greater reported effect against aging than Pinealon.

2015Advances in gerontology = Uspekhi gerontologii

All 13 Vesugen studies by area Open the Scientific page

Key Vesugen studies

Studies in people come first, then studies in animals and in the lab.

People
[The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]
Kitachev et al. 2014 · Advances in gerontology = Uspekhi gerontologii · 41 people · cited by 2
1 result
People
[The role of vasoactive peptid in lower limbs chronic arterial insufficiency treatment]
Kitachov et al. 2013 · Advances in gerontology = Uspekhi gerontologii · 41 people · cited by 1
1 result
People
[EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION]
Meshchaninov et al. 2015 · Advances in gerontology = Uspekhi gerontologii · cited by 1
3 results
Lab cells
Peptidegic stimulation of differentiation of pineal immune cells
Linkova et al. 2011 · Bulletin of experimental biology and medicine · cited by 2
2 results
Lab cells
Effect of short peptides on neuronal differentiation of stem cells
Caputi et al. 2019 · International journal of immunopathology and pharmacology · cited by 43
2 results

All 13 Vesugen (KED) studies

Vesugen clinical trials

ClinicalTrials.gov lists no trial of Vesugen. A trial under another name may exist.

Status and safety

Is Vesugen approved?

FDA

United States

Status unknown

Status unknown.

EMA

European Union

Status unknown

Status unknown.

WADA

Sport

Not recorded

Status unknown.

Regulatory status not recorded. Status unknown.

Laws and labels change, so check the regulator for the current status.

Vesugen side effects and safety

PepBank has 1 safety result from studies of Vesugen. 1 of them come from studies in people.

Safety results from studies (1)

In patients with several diseases and organic brain syndrome in remission, Vesugen did not change chromatin condensation. (Advances in gerontology = Uspekhi gerontologii, 2015)

See every safety result on the Scientific page

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The guide describes blood vessel aging research. It reports a use pattern, without proof of safety or benefit.

Reported routines and cautions

What people use it for

Community interest in blood vessel aging researchS1

Reported regimens

Regimens that community sources report for Vesugen. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Community interest in blood vessel aging research	subcutaneous injection	0.5 to 2 mg per dose	once daily	10 to 20 days	Single non-vendor guide. The underlying community reports were not independently verified.	S1

Community sources

S1Vesugen dosage, protocols and mixing | Vial Guide (opens in a new tab)vialguide.com

Gaps

This is one secondary guide. It does not identify the underlying community reports. Other regimens exist in the guide. No official medicine label was established. Product purity and actual use were not independently tested.

Questions and more

Ask a question about Vesugen

The answer links to every study it uses.

What does the evidence say about Vesugen?Is Vesugen tested in people?Compare with Humanin Compare with NMN (nicotinamide mononucleotide)

Sources

Database: PepBank data for Vesugen (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about Vesugen

Curo is a peptide shop. PepBank and Curo have the same owner. See the Curo catalog (opens in a new tab).

Vesugen (KED)

Also known as KED, Lys-Glu-Asp, Vesugen, Vesugen peptide, Vezugen

What it is

Synthetic analog, 3 amino acids

Approval

Regulatory status not recorded

In sport

Status unknown

Studies

13 studies with results. 10 of them gave Vesugen, with 23 results.
5 in people18 in lab cells

Best study in people

Non-randomized trial with 41 people (2014)

Clinical trials

None registered

Community use

Community interest in blood vessel aging research

Context

Route

Amount

How often

How long

Agreement

Sources

Community interest in blood vessel aging research

subcutaneous injection

0.5 to 2 mg per dose

once daily

10 to 20 days

Single non-vendor guide. The underlying community reports were not independently verified.

Vesugen (KED)

Vesugen (KED) at a glance

What is Vesugen?

Vesugen (KED) structure and chemistry